Indications for use of vaccine (6)

Polio vaccine is recommended for:
- All infants from two months of age
- Travellers to areas or countries where poliomyelitis is epidemic or endemic and their last dose of polio vaccine has been 10 or more years ago (7 & 8). See Clinical Update. www.nathnac.org/healthprofessionals/clinical/Nathnac-HealthProfessionals-ClinicalUpdate-PolioVaccine.html
- Individuals not previously immunised

Availability of vaccine

Beginning late September, 2004, oral polio vaccine is being eliminated from UK vaccine schedules. This change has been made recognizing the decreased risk of imported wild type polio following the global efforts at polio eradication. The change reflects efforts to simplify paediatric vaccine schedules and to eliminate the small risk of vaccine associate paralytic poliomyelitis from OPV. See the CMO letter, 10th August 2004. http://www.dh.gov.uk/assetRoot/04/08/73/47/04087347.pdf

Changes to the UK vaccine schedules also affect the vaccines offered for foreign travel. Deliveries of the new vaccines will begin on the 27th September 2004 and all GP practices and pharmacies should have received supplies by the 8th October. Details of the vaccines can be found in the summary table below.
# Vaccine schedules

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Manufacturer/ distributor</th>
<th>Schedule</th>
<th>Length of protection</th>
<th>Age range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inactivated Polio Vaccine (Salk) IPOL® (Will continue to be available, but not widely recommended.)</td>
<td>Aventis Pasteur MSD</td>
<td>Infants: 3 doses, one month apart, booster age 4 - 6 years Adults: 2nd dose 1-2 months after 1st. 3rd dose after a further 6-12 months.</td>
<td>Adults and Children: 10 years (In adults 1 booster dose is sufficient for life (7))</td>
<td>Adults &amp; children from 6 weeks of age</td>
</tr>
<tr>
<td>Pediacel® (diphtheria, tetanus, 5 component acellular pertussis, inactivated polio vaccine and Haemophilus influenzae type b vaccine – DTaP/IPV/Hib)</td>
<td>Aventis Pasteur MSD</td>
<td>Primary immunisation at 2, 3 and 4 months</td>
<td>Three years DTaP/IPV and life for Hib</td>
<td>2 months – 10 years</td>
</tr>
<tr>
<td>Repevax® (low dose diphtheria, tetanus 5 component acellular pertussis and inactivated polio vaccine – dTaP/IPV)</td>
<td>Aventis Pasteur MSD</td>
<td>Pre-school booster; single dose</td>
<td>Seven years for the dT/IPV. No data on aP.</td>
<td>3 years, 4 months – 5 years</td>
</tr>
<tr>
<td>Revaxis® (low dose diphtheria, tetanus and inactivated polio vaccine Td/IPV)</td>
<td>Aventis Pasteur MSD</td>
<td>Single dose booster.</td>
<td>10 years.</td>
<td>10 years and over</td>
</tr>
<tr>
<td>Oral Polio Vaccine (Sabin) (Will be discontinued by October 2004)</td>
<td>GlaxoSmith Kline</td>
<td>Infants: 3 doses, one month apart, booster age 4 - 6 years Adults: 3 doses one month apart.</td>
<td>Adults and children: 10 years</td>
<td>Adults &amp; children from 2 months of age</td>
</tr>
</tbody>
</table>

A course started with OPV can be completed or reinforced with IPV and vice versa (6).
Interrupted courses

**OPV**: (1)
Resume course to complete a primary course of 3 doses, no matter the time interval that has elapsed.

**IPV**: (2)
Children: time intervals between doses longer than those recommended for routine primary immunization do not necessitate additional doses as long as a final total of four doses is reached.
Adults: those who have had 1 or 2 doses in the past should receive the remaining 1 or 2 doses. It does not matter how long the interval is from the earlier doses.

**Pediacel** (3)
There is no data regarding the administration of Pediacel® for one or two doses and use of different vaccines for other doses. Therefore it is recommended that infants who receive Pediacel® for the first dose should also receive this vaccine for the second and third doses of the primary immunisation series.

**Repevax®** (2) & **Revaxis®** (3)
Not applicable, single dose.

Contraindications

- History of hypersensitivity to the vaccine or its components
- Acute febrile illness / intercurrent infection

**Contraindication specific to OPV** (1)
- Current GI upset
- Individuals with impaired immune response
- Siblings and other household contacts of immunosuppressed individuals
- Pregnancy

**Contraindication to Pediacel®** (3) **Repevax®** (4) & **Revaxis®** (5)
- Neurological complications of unknown origin within 7 days of previous vaccination.
Adverse Events

OPV (1)
- Non-specific signs and symptoms such as fever, malaise, headache, vomiting and diarrhoea have been described (1).
- Paralysis temporally associated with vaccination, termed Vaccine Associated Paralytic Poliomyelitis (VAPP) has been reported rarely in vaccine recipients or contacts of vaccine recipients. The risk of VAPP is higher after the first dose of OPV than after subsequent doses, ranging from 1 case per 1.4 million to 1 case per 2.4 million first doses administered. Among immunocompetent persons, 83% of cases among vaccine recipients and 63% of cases among contacts occur following administration of the first dose (9).
- Anaphylaxis has been reported extremely rarely. As polio vaccine is usually given with other vaccines a causal relationship may be difficult to establish (1).

IPV (2)
- A mild erythematous reaction at the site of injection and moderate fever occasionally occur (3).

Pediacel® (3)
- Clinical trials have shown that adverse reactions following polio vaccine tend to be mild and transient. They can include soreness, erythema and induration at the injection site.
- More serious reactions e.g. febrile convulsions, gastrointestinal problems and irritability have been rarely reported.

Repevax® (4)
- Clinical trials have shown that adverse reactions following polio vaccine tend to be mild and transient. They can include soreness, erythema and induration at the injection site.
- More serious reactions e.g. gastrointestinal problems, dermatitis and arthralgia have been rarely reported.

Revaxis® (5)
- Clinical trials have shown that adverse reactions following polio vaccine tend to be mild and transient. They can include soreness, erythema and induration at the injection site.
- More serious reactions e.g. gastrointestinal problems, vertigo and malaise have been rarely reported.
References


2. Summary of Product Characteristics: *Polio Vaccine (Inactivated.)* Maidenhead: Aventis Pasteur; 2004


Back to top

Reading List


Back to top

Links
Centers for Disease Control (CDC)  www.cdc.gov/travel/diseases/polio.htm

Committee to Advise on Tropical Medicine and Travel (CATMAT) www.hc-sc.gc.ca/pphb-dgpsp/tmp-pmv/info/polio_e.html